PDS Biotechnology/$PDSB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ticker
$PDSB
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
24
ISIN
US70465T1079
Website
PDSB Metrics
BasicAdvanced
$82M
-
-$0.94
1.24
-
Price and volume
Market cap
$82M
Beta
1.24
52-week high
$4.42
52-week low
$0.85
Average daily volume
665K
Financial strength
Current ratio
2.325
Quick ratio
2.189
Long term debt to equity
28.624
Total debt to equity
84.788
Interest coverage (TTM)
-7.98%
Management effectiveness
Return on assets (TTM)
-38.06%
Return on equity (TTM)
-119.22%
Valuation
Price to book
3.64
Price to tangible book (TTM)
3.64
Price to free cash flow (TTM)
-1.985
Growth
Earnings per share change (TTM)
-31.57%
3-year earnings per share growth (CAGR)
3.68%
What the Analysts think about PDSB
Analyst ratings (Buy, Hold, Sell) for PDS Biotechnology stock.
PDSB Financial Performance
Revenues and expenses
PDSB Earnings Performance
Company profitability
PDSB News
AllArticlesVideos
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC
GlobeNewsWire·4 days ago
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewsWire·3 weeks ago
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase
GlobeNewsWire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PDS Biotechnology stock?
PDS Biotechnology (PDSB) has a market cap of $82M as of June 13, 2025.
What is the P/E ratio for PDS Biotechnology stock?
The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of June 13, 2025.
Does PDS Biotechnology stock pay dividends?
No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of June 13, 2025.
When is the next PDS Biotechnology dividend payment date?
PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.
What is the beta indicator for PDS Biotechnology?
PDS Biotechnology (PDSB) has a beta rating of 1.24. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.